Veracyte EV/EBIT VCYT

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 27.2×
3-year median: 64.9×
Against its 3-year history: 17th; percentile: 0 is its lowest day, 100 its highest
3-year range: 20.7× to 127×
Peer median: 35.1×

Veracyte's EV/EBIT is 27.2× as of Oct 23, 2026.

That is below its 3-year median of 64.9×, lower than on 83% of days in the last 3 years.

Over that time it ranged from 20.7× in Mar 2026 to 127× in Feb 2025.

The median for 10 diagnostics and research stocks of a similar size is 35.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.2×	20.7×	64.1×
2025	64.3×	51.7×	127×
2024	64.9×	56.6×	91.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.

Company	EV/EBIT
VCYTVeracyte	27.2×
CDNACareDx	29.3×
BLLNBillionToOne	107×
LNTHLantheus	20.6×
CAICaris Life Sciences	56.4×
BIOBio-Rad Laboratories	40.2×
RVTYRevvity	46.0×
MEDPMedpace	31.4×
LHLabcorp	21.6×
DGXQuest Diagnostics	19.5×
NRCNRC Health	38.8×
Peer median	35.1×

Where Veracyte ranks

#8of 25Diagnostics and research stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Veracyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.